We are live on
!
Find out more
HS
HighVista Strategies Portfolio holdings
AUM
$362M
1-Year Est. Return
230.96%
This Fund
S&P 500
This Quarter
Est. Return
+6.61%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$216M
AUM Growth
-$2.51M
(-1.1%)
Cap. Flow
-$7.44M
Cap. Flow
% of AUM
-3.45%
Top 10 Holdings %
Top 10 Hldgs %
35.07%
Holding
172
New
38
Increased
33
Reduced
47
Closed
40
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AMED
Amedisys
AMED
|
+$3.63M |
| 2 |
Capri Holdings
CPRI
|
+$3.52M |
| 3 |
IDEAYA Biosciences
IDYA
|
+$3.22M |
| 4 |
SPLK
Splunk Inc
SPLK
|
+$3.13M |
| 5 |
Structure Therapeutics
GPCR
|
+$2.41M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$5.49M |
| 2 |
MoonLake Immunotherapeutics
MLTX
|
+$3.86M |
| 3 |
BKI
Black Knight, Inc. Common Stock
BKI
|
+$3.59M |
| 4 |
MMP
Magellan Midstream Partners, L.P.
MMP
|
+$3.49M |
| 5 |
AJRD
Aerojet Rocketdyne Holdings
AJRD
|
+$3.38M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 46.09% |
| 2 | Technology | 13.85% |
| 3 | Consumer Discretionary | 6.89% |
| 4 | Financials | 3.51% |
| 5 | Communication Services | 3.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
argenx
ARGX
$54.1B
| $525K | 0.24% |
1,067
-711
| -40% | -$348K |
|
102
Constellium
CSTM
$4.05B
| $524K | 0.24% |
28,794
-900
| -3% | -$15.9K |
|
|
ETNB
103
DELISTED
89bio
ETNB
| $522K | 0.24% |
33,792
-9,847
| -23% | -$165K |
|
104
Ultragenyx Pharmaceutical
RARE
$2.66B
| $520K | 0.24% |
14,591
+7,265
| +99% | +$288K |
|
105
United Therapeutics
UTHR
$22.1B
| $519K | 0.24% |
2,299
+557
| +32% | +$128K |
|
106
Krystal Biotech
KRYS
$9.68B
| $509K | 0.24% |
4,392
+1,862
| +74% | +$227K |
|
107
Autoliv
ALV
$8.96B
| $506K | 0.23% |
5,244
-600
| -10% | -$57.5K |
|
108
Revolution Medicines
RVMD
$44.1B
| $498K | 0.23% |
+18,005
| New | +$534K |
|
|
ITCI
109
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $497K | 0.23% |
+9,545
| New | +$556K |
|
110
TKO Group
TKO
$14.2B
| $497K | 0.23% |
+5,907
| New | +$548K |
|
|
VRNA
111
DELISTED
Verona Pharma
VRNA
| $487K | 0.23% |
29,873
-4,154
| -12% | -$80K |
|
112
Amylyx Pharmaceuticals
AMLX
$2.63B
| $482K | 0.22% |
26,349
+12,601
| +92% | +$266K |
|
113
Celldex Therapeutics
CLDX
$3.48B
| $481K | 0.22% |
17,482
-7,260
| -29% | -$228K |
|
|
LKFT
114
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.88B
| $472K | 0.22% |
+13,647
| New | +$531K |
|
115
Incyte
INCY
$24.5B
| $471K | 0.22% |
8,158
-2,721
| -25% | -$172K |
|
|
PNT
116
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $465K | 0.22% |
+69,744
| New | +$580K |
|
117
TAL Education Group
TAL
$6.75B
| $458K | 0.21% |
+50,300
| New | +$353K |
|
|
ALPN
118
DELISTED
Alpine Immune Sciences Inc
ALPN
| $456K | 0.21% |
39,861
-50,426
| -56% | -$621K |
|
119
Natera
NTRA
$45.1B
| $445K | 0.21% |
10,066
+2,811
| +39% | +$143K |
|
120
Madrigal Pharmaceuticals
MDGL
$12.4B
| $445K | 0.21% |
3,045
+249
| +9% | +$46.9K |
|
121
Prothena Corp
PRTA
$473M
| $444K | 0.21% |
9,195
+2,789
| +44% | +$166K |
|
122
Syndax Pharmaceuticals
SNDX
$1.81B
| $428K | 0.2% |
29,490
-4,086
| -12% | -$77.3K |
|
123
Geron
GERN
$1.05B
| $426K | 0.2% |
200,893
+78,189
| +64% | +$212K |
|
124
4D Molecular Therapeutics
FDMT
$600M
| $425K | 0.2% |
+33,419
| New | +$559K |
|
125
Vera Therapeutics
VERA
$2.17B
| $424K | 0.2% |
+30,902
| New | +$530K |
|
Similar funds
SIAG
MS
WTFG
A6
PI
ACM
PPG
PWC
HighVista Strategies's Q3 2023 Portfolio in Review
As of Q3 2023, HighVista Strategies held 172 positions worth $216M, down 1.1% from $219M the previous quarter. Its ten largest holdings account for 35% of the portfolio.
HighVista Strategies withdrew a net $7.44M in Q3 2023, closing 40 positions and reducing 47 holdings. Its most notable exit was IVERIC bio, Inc. Common Stock, an estimated $5.49M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 46% of assets, down from 47% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, HighVista Strategies opened a new position in Amedisys worth $3.67M.
- HighVista Strategies's largest Q3 2023 buy was Amedisys: 39,250 shares worth $3.67M.
- HighVista Strategies added most to Merus in Q3 2023, an estimated $2.15M increase.
- HighVista Strategies's biggest Q3 2023 reduction was MoonLake Immunotherapeutics, cutting an estimated $3.86M.
- HighVista Strategies fully exited IVERIC bio, Inc. Common Stock in Q3 2023, selling an estimated $5.49M.
- HighVista Strategies's ten largest holdings make up 35% of its $216M portfolio in Q3 2023.
- HighVista Strategies opened 38 new positions and closed 40 in Q3 2023.
- HighVista Strategies's portfolio value fell 1.1% quarter-over-quarter to $216M.
Based on HighVista Strategies's 13F filing for Q3 2023, filed 14 Nov 2023.